BlackRock Advisors’s Travere Therapeutics TVTX Stock Holding History

BlackRock Advisors’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$1.15M	Buy	60,539 +2,587	+4%	+$52.9K	﹤0.01%	1787
2016 Q3	$1.3M	Sell	57,952 -7,300	-11%	-$139K	﹤0.01%	1679
2016 Q2	$1.16M	Sell	65,252 -17,290	-21%	-$280K	﹤0.01%	1695
2016 Q1	$1.13M	Buy	82,542 +1,298	+2%	+$19.7K	﹤0.01%	1679
2015 Q4	$1.57M	Sell	81,244 -7,308	-8%	-$146K	﹤0.01%	1510
2015 Q3	$1.79M	Sell	88,552 -2,244	-2%	-$66.5K	﹤0.01%	1400
2015 Q2	$3.01M	Buy	90,796 +69,769	+332%	+$1.91M	﹤0.01%	1129
2015 Q1	$504K	Buy	21,027 +9,791	+87%	+$149K	﹤0.01%	2065
2014 Q4	$138K	Sell	11,236 -464	-4%	-$4.8K	﹤0.01%	2857
2014 Q3	$106K	Buy	11,700 +2,736	+31%	+$32.2K	﹤0.01%	2971
2014 Q2	$105K	Sell	8,964 -848	-9%	-$11.5K	﹤0.01%	3026
2014 Q1	$208K	Buy	+9,812	New	+$151K	﹤0.01%	2616

Other funds holding TVTX

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors's TVTX Position: Q4 2016 in Review

BlackRock Advisors increased its Travere Therapeutics (TVTX) stake by 4.5% in Q4 2016, buying an estimated $52.9K and bringing the position to 60,539 shares worth $1.15M. The position accounts for ﹤0.01% of the portfolio, ranked #1787.

BlackRock Advisors first reported a position in TVTX in Q1 2014 and has held it in 12 quarters since. The position peaked at $3.01M in Q2 2015. 121 funds tracked by Wall St. Rank hold TVTX as of Q4 2016.

BlackRock Advisors held 60,539 shares of Travere Therapeutics worth $1.15M as of Q4 2016.
BlackRock Advisors bought 2,587 Travere Therapeutics shares in Q4 2016, an estimated $52.9K.
Travere Therapeutics made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1787 holding.
BlackRock Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 12 quarters since.
BlackRock Advisors's Travere Therapeutics position peaked at $3.01M in Q2 2015.
121 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.